EPISODE · Dec 18, 2025 · 16 MIN
RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
from WTR Small-Cap Spotlight · host Water Tower Research
Send us Fan MailIn this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in treating hard-to-reach hypovascular tumors like pancreatic cancer. The conversation also covers RenovoCath’s commercialization strategy and key milestones in its Phase 3 clinical trial aimed at proving the platform’s delivery superiority over the current standard of care.
NOW PLAYING
RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
No transcript for this episode yet
Similar Episodes
Apr 22, 2025 ·32m
Feb 27, 2025 ·0m
Sep 20, 2024 ·57m
Aug 7, 2024 ·16m